| Name | Title | Contact Details |
|---|---|---|
Eliot Lurier |
Interim CFO | Profile |
Chad Hymel |
Director of Supply Chain | Profile |
Ashley Cate |
Associate Director, Finance | Profile |
Preston Brown |
VP, Product Operations | Profile |
Khoi Le |
Senior Director of R&D, Software Development, Scientific Computing/Informatics | Profile |
C4 Therapeutics is pioneering a new class of drugs. C4`s technology platform produces small molecule drugs that harness machinery already present in cells to selectively target disease-relevant proteins for degradation. Our approach has the potential to address a broad range of diseases including cancer, infectious disease, and autoimmune disorders.
Seer is a life sciences and health data company focused on capturing and translating deep molecular insights from the proteome to enable early detection of cancer and neurological diseases, drive earlier treatment, and improve patient outcomes.
CervoMed is a public, Boston, MA-based company advancing CNS-focused therapeutics to benefit patients with neurodegenerative diseases. CervoMed was launched in 2014 as EIP Pharma, Inc, by R&D executives from the pharmaceutical and biotech industry. In August, 2023 EIP Pharma merged with Diffusion Pharmaceuticals, retaining EIPs development pipeline, but changing their name to CervoMed (CRVO). For more information about the company and updates, please visit www.cervomed.com/ or follow us on Twitter at @Cervo_Med.
AiLife Diagnostics is a CAP/CLIA laboratory that provides end-to-end genomic testing, interpretation services, and NGS analysis tool.
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Our pipeline consists of small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Our lead drug candidate is tipifarnib, a farnesyl transferase inhibitor, which is currently being studied in multiple Phase 2 clinical trials in solid tumor and hematologic indications. Our pipeline also includes KO-947, an ERK inhibitor, currently in a Phase 1 dose-escalation trial, and KO-539, a menin-MLL inhibitor, currently in preclinical development.